chromosome 20 putative open reading frame 181Genealiases: []
Q-omics provides the consensus-scored C20orf181 profile across patient tissues and cancer cell-line models. C20orf181 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, C20orf181 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, C20orf181 RNA expression shows 6,423 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, UCEC, and STAD as cancer lineages where C20orf181 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C20orf181 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C20orf181 survival associations across molecular data types. C20orf181 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C20orf181 RNA expression–survival associations across cancer types. High C20orf181 expression shows unfavorable associations in TGCT, COAD, LUAD, GBM and OV, but favorable associations in BLCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for C20orf181 RNA expression.
This table summarizes C20orf181 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for C20orf181. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C20orf181 shows lower tumor expression in UCEC and higher tumor expression in BRCA. The UCEC box plot shows higher C20orf181 RNA expression in normal versus tumor tissue (log2 FC = −0.149, t-test p = .027).
This table shows molecular features associated with C20orf181 in patient tissues and cancer cell lines. In patient samples, C20orf181 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
